PTEN and prostate neoplasm: Because PTEN loss is commonly focal and subclonal in primary prostate tumors [4, 14–16], in situ methodologies for PTEN loss detection may be preferable to methods that assess copy number variation based on nucleic acid extraction, such as sequencing.